15.6 C
New York
Tuesday, April 23, 2024
HomeMarkets
Markets

Cowen Analyst Likes Intercept Pharmaceuticals, ACADIA Pharmaceuticals And Raptor Pharmaceutical

By Insider Scoop
0
51
psw-placeholder
psw-placeholder

Courtesy of Benzinga.

Related ICPT
Mid-Afternoon Market Update: Crude Oil Jumps 7.5%; Visa Shares Climb On Earnings Beat
Intercept Pharmaceuticals Soars 20%, Possible Short Squeeze
Intercept Pharmaceuticals' OCA Now Breakthrough Therapy – Analyst Blog (Zacks)

Related ACAD
Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2
Benzinga's Top Initiations
Qiagen (QGEN) Disappoints with Q4 Earnings, Revenue Miss – Analyst Blog (Zacks)

Speaking on CNBC’s Fast Money, Ritu Baral of Cowen and Company said that Intercept Pharmaceuticals Inc (NASDAQ: ICPT) is a buy. The company has received a breakthrough status by the FDA and it is about to start a phase 3 in the NASH program, said Baral. She added that we are going to see a filing for a lead program that has a potential to get approved by the FDA at the end of 2015 or early 2016.

She likes ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) because of Parkinson’s psychosis treatment, which has a billion plus market. It has a breakthrough status by the FDA and the company has been a topic in numerous acquisition discussions.

Baral is bullish on Raptor Pharmaceutical Corp. (NASDAQ: RPTP). The stock has been struggling recently because of the weak Q4, but Baral thinks that the catalyst for this stock will come in May when the data of pediatric NASH program gets released.

Latest Ratings for ICPT

Date Firm Action From To
Jan 2015 Deutsche Bank Maintains Buy
Dec 2014 Citigroup Maintains Buy
Dec 2014 Bank of America Reinstates Buy

View More Analyst Ratings for ICPT
View the Latest Analyst Ratings

Posted-In: Cowen and Company Ritu BaralAnalyst Color CNBC Analyst Ratings Media

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,336FansLike
396,312FollowersFollow
2,290SubscribersSubscribe

Latest Articles

Load more

Note: The material presented in this commentary is provided for informational purposes only and is based upon information that is considered to be reliable. However, neither PSW Investments, LLC d/b/a PhilStockWorld (PSW) nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither PSW nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance, including the tracking of virtual trades and portfolios for educational purposes, is not necessarily indicative of future results. Neither Phil, Optrader, or anyone related to PSW is a registered financial adviser and they may hold positions in the stocks mentioned, which may change at any time without notice. Do not buy or sell based on anything that is written here, the risk of loss in trading is great.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only intended at the moment of their issue as conditions quickly change. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.

Contact us: support@philstockworld.com

© Copyright - PSW, LLC.

2024
0
Would love your thoughts, please comment.x
()
x